Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Current Cancer Therapy Reviews is Scopus-indexed (Q3, CiteScore 1.3), WoS ESCI. It is covered by India's One Nation One Subscription scheme for reading access. Published by Bentham Science Publishers.
Checked against the index lists dated .
ISSN 1573-3947Verify ISSN ↗1875-6301Verify ISSN ↗
Publisher: Bentham Science Publishers
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 317 / 428 | 26th | Q3 |
| Cancer Research | 200 / 233 | 14th | Q4 |
| Molecular Medicine | 162 / 179 | 9th | Q4 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2006–present, best quartile Q3, CiteScore 1.3.
Current Cancer Therapy Reviews is Q3 in Oncology (rank 317 of 428), Q4 in Cancer Research (rank 200 of 233) and Q4 in Molecular Medicine (rank 162 of 179), by CiteScore 2025.
Current Cancer Therapy Reviews is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 1.3, which places it in quartile Q3 at the 26th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.214, quartile Q4, with an H-index of 20.
Current Cancer Therapy Reviews is published by Bentham Science Publishers. Its print ISSN is 1573-3947 and its online ISSN is 1875-6301.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Emerging Sources Citation Index.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Current Cancer Therapy Reviews has an h-index of 23 and a 2-year mean of 0.92 citations per paper (OpenAlex). Its Scopus CiteScore is 1.3, quartile Q3. On 2-year citations it ranks #298 of 424 Scopus journals in Oncology.
Current Cancer Therapy Reviews published 39 papers in 2025; its busiest recent year was 2024 with 99. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 94 research articles (2024–2026), authors are most often from India (54.6%), China (12.8%) and Iran (10.5%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (2.3 per 1,000 papers). The Problematic Paper Screener flags 4 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.